Hero

Celyad doses first AML patient at final dose level in CYAD-01 THINK trial and treats first patient with second cycle of therapy

Celyad doses first AML patient at final dose level in CYAD-01 THINK trial and treats first patient with second cycle of therapy

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

Latest News

Celyad doses first AML patient at final dose level in CYAD-01 THINK trial and treats first patient with second cycle of therapy

Celyad doses first AML patient at final dose level in CYAD-01 THINK trial and treats first patient with second cycle of therapy

Celyad announces closing of global offering

Celyad announces closing of global offering

Celyad announces pricing of $47.3 million global offering

Celyad announces pricing of $47.3 million global offering

Discover all news

Carousel

Social Feed

Listen to David Sallman's podcast on CAR-T case study in AML https://t.co/Xplm3kgT9a

1 minute ago

Listen to David Sallman's podcast on CAR-T case study in AML https://t.co/Xplm3kgT9a

Read the publication about Manufacturing development and clinical production of NKG2D chimeric antigen receptor–exp… https://t.co/YC29ZpKpI8

1 week ago

Read the publication about Manufacturing development and clinical production of NKG2D chimeric antigen receptor–exp… https://t.co/YC29ZpKpI8

Peggy Sotiropoulou , R&D manager at Celyad, quoted in the great article of GEN about solid progress in CAR-T cells… https://t.co/hgJ9deEg5o

2 weeks ago

Peggy Sotiropoulou , R&D manager at Celyad, quoted in the great article of GEN about solid progress in CAR-T cells… https://t.co/hgJ9deEg5o

HC Wainwright: Celyad's CAR-T Pipeline Has Potential https://t.co/QeF5JIrO5v

2 weeks ago

HC Wainwright: Celyad's CAR-T Pipeline Has Potential https://t.co/QeF5JIrO5v

Listen to David Sallman's podcast on CAR-T case study in AML https://t.co/Xplm3kgT9a

1 minute ago

Listen to David Sallman's podcast on CAR-T case study in AML https://t.co/Xplm3kgT9a

Read the publication about Manufacturing development and clinical production of NKG2D chimeric antigen receptor–exp… https://t.co/YC29ZpKpI8

1 week ago

Read the publication about Manufacturing development and clinical production of NKG2D chimeric antigen receptor–exp… https://t.co/YC29ZpKpI8

Peggy Sotiropoulou , R&D manager at Celyad, quoted in the great article of GEN about solid progress in CAR-T cells… https://t.co/hgJ9deEg5o

2 weeks ago

Peggy Sotiropoulou , R&D manager at Celyad, quoted in the great article of GEN about solid progress in CAR-T cells… https://t.co/hgJ9deEg5o

HC Wainwright: Celyad's CAR-T Pipeline Has Potential https://t.co/QeF5JIrO5v

2 weeks ago

HC Wainwright: Celyad's CAR-T Pipeline Has Potential https://t.co/QeF5JIrO5v